FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281790089> ?p ?o ?g. }

• W4281790089 endingPage "e12622" @default.
• W4281790089 startingPage "e12622" @default.
• W4281790089 abstract "e12622 Background: Despite that AC-THP regimen is one of the commonly used regimens for neoadjuvant treatment of HER2-positive breast cancer, previous studies showed that pCR rate rarely exceeds 70%. We hypothesized that prolonged dual anti-HER2 therapy can increase pCR rate in neoadjuvant therapy. In this study, we designed a single-arm trial of ACHP-THP regimen (continuous dual anti-HER2 therapy of trastuzumab and pertuzumab) in neoadjuvant therapy of HER2 positive breast cancer. To minimize adverse cardiovascular events, we used pegylated liposomal doxorubicin (PLD) and Nab-Paclitaxel (Nab-P) instead of doxorubicin and paclitaxel. We aimed to examine whether continuous dual anti-HER2 therapy can boost pCR rate in the neoadjuvant therapy. The cardiotoxicity was closely monitored when the anti-HER2 therapy was combined with PLD and Nab-P respectively. Methods: Upon approval by the Medical Ethics Committee of Xijing Hospital, patients with HER2-positive breast cancer (cT2-3/N0-1/M0) receiving neoadjuvant therapy, were enrolled. The patients were treated with PldCHP (pegylated liposomal doxorubicin 35mg/m 2 , cyclophosphamide 600mg/m 2 , trastuzumab 8 mg/kg loading, then 6 mg/kg, pertuzumab 840 mg loading, then 420 mg, iv, q3w) for 4 cycles followed by Nab-PHP (Nab-Paclitaxel 260mg/m 2 , trastuzumab 6 mg/kg, pertuzumab 420 mg, iv, q3w) for 4 cycles, with strict monitoring of cardiotoxicity. The primary endpoint was pCR rate, and secondary endpoint was cardiotoxicity during neoadjuvant therapy. Results: From January 2020 to October 2021, a total of 96 patients were recruited. Among the 96 patients with a median age of 49 (21-71), 58 patients were HR positive and 42 patients had positive lymph node status. Overall, the pCR rate was 80.2% (77/96). The ER-positive tumor achieved a higher pCR rate than ER-negative tumor (82.8% vs 76.3%, p=0.439), but the difference was statistically insignificant. Multivariate regression analysis showed that for participants older than 30, HER2 3+ (IHC) showed a statistically significant positive influence on pCR rate. The common adverse reactions of grade ≥3 were neutropenia (30.2%), asthenia (8.3%), and peripheral sensory neuropathy (7.3%). Left ventricular insufficiency was detected in 4 patients, and no cardiotoxic events higher than grade 2 occurred during the neoadjuvant therapy. There was no treatment-related death. Conclusions: The PldCHP---Nab-PHP regimen is a feasible and effective neoadjuvant therapy for early stage HER2-positive breast cancer, showing high pCR rate and acceptable cardiotoxicity. These results support a further random controlled trial testing for continuous dual anti-HER2 therapy combined with PLD in neoadjuvant or adjuvant therapy of HER2 positive breast cancer." @default.
• W4281790089 created "2022-06-13" @default.
• W4281790089 creator A5004351194 @default.
• W4281790089 creator A5011982545 @default.
• W4281790089 creator A5015614663 @default.
• W4281790089 creator A5033819908 @default.
• W4281790089 creator A5050362819 @default.
• W4281790089 creator A5054892027 @default.
• W4281790089 creator A5063123223 @default.
• W4281790089 creator A5069095052 @default.
• W4281790089 creator A5073216396 @default.
• W4281790089 creator A5075742926 @default.
• W4281790089 date "2022-06-01" @default.
• W4281790089 modified "2023-10-07" @default.
• W4281790089 title "Neoadjuvant pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by nab-paclitaxel (Nab-P) as primary chemotherapy continuously combined with dual HER2 blockage for HER2-positive breast cancer: A single-arm phase 2 trial (Brecan Trial)." @default.
• W4281790089 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e12622" @default.
• W4281790089 hasPublicationYear "2022" @default.
• W4281790089 type Work @default.
• W4281790089 citedByCount "0" @default.
• W4281790089 crossrefType "journal-article" @default.
• W4281790089 hasAuthorship W4281790089A5004351194 @default.
• W4281790089 hasAuthorship W4281790089A5011982545 @default.
• W4281790089 hasAuthorship W4281790089A5015614663 @default.
• W4281790089 hasAuthorship W4281790089A5033819908 @default.
• W4281790089 hasAuthorship W4281790089A5050362819 @default.
• W4281790089 hasAuthorship W4281790089A5054892027 @default.
• W4281790089 hasAuthorship W4281790089A5063123223 @default.
• W4281790089 hasAuthorship W4281790089A5069095052 @default.
• W4281790089 hasAuthorship W4281790089A5073216396 @default.
• W4281790089 hasAuthorship W4281790089A5075742926 @default.
• W4281790089 hasConcept C121608353 @default.
• W4281790089 hasConcept C126322002 @default.
• W4281790089 hasConcept C143998085 @default.
• W4281790089 hasConcept C203092338 @default.
• W4281790089 hasConcept C2776694085 @default.
• W4281790089 hasConcept C2776755627 @default.
• W4281790089 hasConcept C2777292972 @default.
• W4281790089 hasConcept C2778233292 @default.
• W4281790089 hasConcept C2778292576 @default.
• W4281790089 hasConcept C2779786085 @default.
• W4281790089 hasConcept C2781164504 @default.
• W4281790089 hasConcept C2781303535 @default.
• W4281790089 hasConcept C2781413609 @default.
• W4281790089 hasConcept C530470458 @default.
• W4281790089 hasConcept C535046627 @default.
• W4281790089 hasConcept C71924100 @default.
• W4281790089 hasConceptScore W4281790089C121608353 @default.
• W4281790089 hasConceptScore W4281790089C126322002 @default.
• W4281790089 hasConceptScore W4281790089C143998085 @default.
• W4281790089 hasConceptScore W4281790089C203092338 @default.
• W4281790089 hasConceptScore W4281790089C2776694085 @default.
• W4281790089 hasConceptScore W4281790089C2776755627 @default.
• W4281790089 hasConceptScore W4281790089C2777292972 @default.
• W4281790089 hasConceptScore W4281790089C2778233292 @default.
• W4281790089 hasConceptScore W4281790089C2778292576 @default.
• W4281790089 hasConceptScore W4281790089C2779786085 @default.
• W4281790089 hasConceptScore W4281790089C2781164504 @default.
• W4281790089 hasConceptScore W4281790089C2781303535 @default.
• W4281790089 hasConceptScore W4281790089C2781413609 @default.
• W4281790089 hasConceptScore W4281790089C530470458 @default.
• W4281790089 hasConceptScore W4281790089C535046627 @default.
• W4281790089 hasConceptScore W4281790089C71924100 @default.
• W4281790089 hasIssue "16_suppl" @default.
• W4281790089 hasLocation W42817900891 @default.
• W4281790089 hasOpenAccess W4281790089 @default.
• W4281790089 hasPrimaryLocation W42817900891 @default.
• W4281790089 hasRelatedWork W2327259730 @default.
• W4281790089 hasRelatedWork W2377079174 @default.
• W4281790089 hasRelatedWork W2560406314 @default.
• W4281790089 hasRelatedWork W2593886517 @default.
• W4281790089 hasRelatedWork W2624925742 @default.
• W4281790089 hasRelatedWork W2751857407 @default.
• W4281790089 hasRelatedWork W2760874931 @default.
• W4281790089 hasRelatedWork W2980453143 @default.
• W4281790089 hasRelatedWork W4229446258 @default.
• W4281790089 hasRelatedWork W4322772378 @default.
• W4281790089 hasVolume "40" @default.
• W4281790089 isParatext "false" @default.
• W4281790089 isRetracted "false" @default.
• W4281790089 workType "article" @default.